Sept. 8 Quick Takes: Detailed APOLLO-B data lift Alnylam shares

Detailed data for patisiran from the APOLLO-B study presented by Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) at the International Symposium on Amyloidosis Thursday lifted the company’s shares $17.44 to $226.30. The RNAi therapy demonstrated an improvement of 14.7 meters in the 6-Minute Walk Test (6-MWT), meeting the study’s primary endpoint. Alnylam gained 49% to $212.01 on Aug. 3 when the company announced patisiran had met the trial’s endpoint; results from the study could help the amyloidosis drug reach a much larger population of patients with the disorder. An sNDA submission is planned late this year.

Autobahn Therapeutics Inc. will use a newly raised $32.7 million venture round to support development of ABX-002 for treatment-resistant depression, with a Phase I trial slated to begin by year-end. Autobahn debuted in 2020 with a $76 million series B Tuesday and plans to move the thyroid receptor β agonist into the clinic for multiple sclerosis. Existing investors Arch Venture Partners, Cowen Healthcare Investments, BVF Partners, Biogen Inc. (NASDAQ:BIIB), Bristol Myers Squibb Co. (NYSE:BMY), Pfizer Ventures, Invus, Section 32, Samsara BioCapital, Alexandria Venture Investments and GT Healthcare participated in the round. Autobahn added that it would assess opportunities for ABX-002 in other indications, including remyelination and multiple sclerosis, based on Phase I data. ...